Apolipoprotein B compared with low-density lipoprotein cholesterol in the atherosclerotic cardiovascular diseases risk assessment
-
Published:2023-09
Issue:
Volume:195
Page:106873
-
ISSN:1043-6618
-
Container-title:Pharmacological Research
-
language:en
-
Short-container-title:Pharmacological Research
Author:
Galimberti Federica,
Casula ManuelaORCID,
Olmastroni Elena
Reference76 articles.
1. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel;Ference;Eur. Heart J.,2017
2. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials;Cholesterol Treatment Trialists;Lancet,2015
3. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges;Sampson;Curr. Atheroscler. Rep.,2012
4. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity;Boren;Curr. Opin. Lipido,2016
5. Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult;Anderson;Can. J. Cardiol. 2016,2016
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献